The competitive environment of traditional Chinese medicine formula granules is increasingly fierce, and traditional Chinese medicine pharmaceutical companies are accelerating the layout

[Pharmaceutical Network Market Analysis] Traditional Chinese medicine formula granules refer to granules made from single-flavored pieces of traditional Chinese medicin.
In recent years, with the acceleration of unified standard work and inter-provincial joint procurement, traditional Chinese medicine formula granules have begun to usher in policy dividend.
Especially since November 1, 2021, the traditional Chinese medicine formula granules have completed the pilot work of more than 20 years and are included in the management of traditional Chinese medicine piece.
After the formal implementation of the filing system, the industry generally believes that the market expansion of traditional Chinese medicine formula granules is imminen.
According to estimates by many institutions, by 2030, the market size of traditional Chinese medicine formula granules will reach 100 billion yua.
In fact, in the policy dividend period, the market continues to expand, and a large number of traditional Chinese medicine companies have begun to usher in good new.
Previously, the annual report of Hongri Pharmaceutical showed that the revenue of traditional Chinese medicine formula granules and decoction pieces business in 2021 was 235 billion yuan, a year-on-year increase of 460%; China Resources 39 annual report showed that the prescription drug business achieved operating income of 350 billion yuan, a year-on-year increase of 76%, of which, The specialty and traditional Chinese medicine formula granule business has achieved rapid growth; Shenwei Pharmaceutical's annual report shows that in 2021, the sales revenue of the traditional Chinese medicine formula granule business will be 693 million yuan, an increase of 25% over the same period of the previous yea.
It is worth noting that at the moment when the capacity of traditional Chinese medicine formula granules is about to expand, many leading pharmaceutical companies are beginning to speed up the layout of the traditional Chinese medicine formula granule industr.
According to public data, in the past year, more than 30 listed companies such as Jilin Aodong, Essence Pharmaceuticals, and Zuoli Pharmaceuticals have clearly laid out Chinese medicine formula granule.
For example, on June 29, 2022, Yibai Pharmaceutical issued an announcement stating that according to the company's strategic planning and business development needs, the company plans to increase the capital of its wholly-owned subsidiary Yibai Formula Granules to invest in the construction of the company's entire industry chain project of traditional Chinese medicine formula granule.
.
In addition, Kangyuan Pharmaceutical has also stated that the company has carried out research on the production process and quality standards of nearly 400 varieties of traditional Chinese medicine formula granules by 2021, has formed stable process and quality standards, and completed production verificatio.
At present, the company has coordinated and arranged production lines, business personnel, et.
, and is actively promoting the filing work in accordance with the regulatory policy of the Jiangsu Provincial Drug Administration on traditional Chinese medicine granule.
In addition to the above companies, there are dozens of listed pharmaceutical companies such as Yiling Pharmaceutical, Panlong Pharmaceutical, Kun Pharmaceutical Group, Tasly, Xintian Pharmaceutical, Foci Pharmaceutical, Yibai Pharmaceutical, Jilin Aodong, Zhenbaodao, Yan'an Bikang, et.
It is also laying out Chinese medicine formula granule.
Among them, new entrants such as Zhenong C.
, Lt.
, Yan'an Bikang, Yibai Pharmaceutical, and Panlong Pharmaceutical were all mentioned last yea.
They are accelerating the progress of research and development or production and construction of traditional Chinese medicine formula granules, and actively respond to market change.
Industry analysts believe that under the continuous deployment of a large number of traditional Chinese medicine enterprises, the competitive environment of traditional Chinese medicine formula granules will begin to change, and the competition will inevitably become more intense in the future, and the market pattern will be change.
It is reported that in the face of the complex market environment, in addition to the overweight layout, some traditional Chinese medicine companies are also actively seeking transformatio.
For example, the 2021 semi-annual report of Buchang Pharmaceutical once stated: "At present, the company is transforming from a sales-oriented company to a research-oriented company; from proprietary Chinese medicines to biological medicines, vaccines, chemical medicines, medical devices, and Internet medicine; and gradually From Chinese localization to globalizatio.
" Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.